There are currently 439 clinical trials in Memphis, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including St. Jude Children's Research Hospital, Saint Jude Children's Research Hospital, Baptist Memorial Hospital and Cancer Center-Memphis and University of Tennessee Health Science Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Trial of Centanafadine Efficacy and Safety in Adults With Attention-deficit/Hyperactivity Disorder and Comorbid Anxiety
NCT06973577
Recruiting
Phase 3b, Randomized, Double-blind, 8-week, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Centanafadine Once Daily Extended-release Capsules for the Treatment of Adults with Attention-deficit/Hyperactivity Disorder and Comorbid Anxiety
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/27/2025
Locations: Clinical Research Site #001 - CNS Healthcare - Memphis, Memphis, Tennessee
Conditions: ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
Register for Updates
Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age
NCT05660980
Recruiting
The purpose of the study is to evaluate the pharmacokinetics (PK), safety, tolerability, and acceptability of a long-acting injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
05/23/2025
Locations: Site 6501, St. Jude Children's Research Hospital CRS, Memphis, Tennessee
Conditions: HIV-1-infection
Register for Updates
Stress Hydrocortisone In Pediatric Septic Shock
NCT03401398
Recruiting
SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the incidence of new and progressive organ dysfunction (primary outcome) and proportion of children with poor outcomes, defined as death or severely imp... Read More
Gender:
ALL
Ages:
Between 1 month and 17 years
Trial Updated:
05/22/2025
Locations: Le Bonheur Children's Hospital, Memphis, Tennessee
Conditions: Septic Shock
Register for Updates
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
NCT05101551
Recruiting
This is a Phase 1, open label, multicenter, dose finding study with dose expansion intended to evaluate the safety and tolerability of talazoparib in combination with conventional chemotherapy. Preliminary estimates of efficacy will be obtain through a dose expansion cohort receiving the maximum tolerated dose from the dose escalation phase of the study. This study aims to determine the safety of talazoparib in combination with conventional chemotherapy and to establish the maximum tolerated do... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/22/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Myeloid Leukemia
Register for Updates
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
NCT05953090
Recruiting
Vulvovaginal skin conditions, namely vaginal atrophy, lichen sclerosus, lichen simplex chronicus and lichen planus affecting the female adult population will be treated with a novel gel dressing to test the short- and long-term safety and efficacy of the device.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: WR-Medical Research Center of Memphis, LLC, Memphis, Tennessee
Conditions: Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva, Lichen Planus of Vulva, Lichen Simplex of Vulva (Disorder)
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Gender:
ALL
Ages:
18 years and below
Trial Updated:
05/21/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Langerhans Cell Histiocytosis
Register for Updates
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
NCT06847269
Recruiting
CAR19PK is a research study evaluating the use of lymphodepleting chemotherapy and chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of refractory and/or relapsed leukemia. For this type of therapy, peripheral (circulating) immune cells are collected and then modified so that they can recognize an antigen, which is a particle present on the surface of a cancer cell. The CD19-CAR T cell product will be manufactured at the St. Jude Children's Research Ho... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/21/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Register for Updates
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
NCT04155034
Recruiting
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee
Conditions: Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
Register for Updates
A Study of Detection of Paroxysmal Events Utilizing Computer Vision and Machine Learning - Nelli
NCT05606575
Recruiting
Nelli is a video-based non-EEG physiological seizure monitoring system. This study is a blinded comparison of Nelli's identified events to gold-standard video EEG review in at-rest pediatric subjects with suspected motor seizures.
Gender:
ALL
Ages:
Between 6 years and 21 years
Trial Updated:
05/20/2025
Locations: The University of Tennessee Health Science Center, Memphis, Tennessee
Conditions: Epilepsy
Register for Updates
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
NCT06376162
Recruiting
The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or NPM1-m acute leukemia based on safety and pharmacokinetics (PK).
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
05/20/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia
Register for Updates
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
NCT04380610
Recruiting
The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients
Gender:
ALL
Ages:
Between 5 years and 50 years
Trial Updated:
05/19/2025
Locations: St Jude Childrens Research Hospital, Memphis, Tennessee +1 locations
Conditions: Sickle Cell Disease, Renal Disease, Glomerular Disease
Register for Updates
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
NCT06233799
Recruiting
The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/19/2025
Locations: University of Tennessee, Memphis, Tennessee
Conditions: Methamphetamine-dependence, Methamphetamine Abuse
Register for Updates